FTISADTSK-13C6,15N2 (TFA)
FTISADTSK-13C6,15N2 TFA is 13C- and 15N-labeled FTISADTSK. FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM)[2].
Product Specifications
UNSPSC
12352209
Target
Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ftisadtsk-13c6-15n2-tfa.html
Purity
96.04
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N[C@@H](CO)C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C([15NH][13C@@H]([13CH2][13CH2][13CH2][13CH2][15NH2])[13C](O)=O)=O)=O)=O)=O)=O)[C@H]([C@@H](C)CC)NC([C@H]([C@H](O)C)NC([C@@H](N)CC1=CC=CC=C1)=O)=O.O=C(C(F)(F)F)O
Molecular Formula
C38 13C6H69F3N8 15N2O18
Molecular Weight
1091.01
References & Citations
[1]Bults P, et al. LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma. Anal Chem. 2016;88 (3) :1871-1877.|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-220.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
